GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.
- Published In:
- JAMA oncology, 11(10), 1186-1193 (2025)
- Authors:
- Dai, Hao(5), Li, Yongqiu, Lee, Yao An(5), Lu, Ying, George, Thomas J, Donahoo, William T, Lee, Kelvin P, Nakshatri, Harikrishna, Allen, John, Guo, Yi, Sun, Ramon C, Guo, Jingchuan, Bian, Jiang
- Database ID:
- RPEP-10592
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10592APA
Dai, Hao; Li, Yongqiu; Lee, Yao An; Lu, Ying; George, Thomas J; Donahoo, William T; Lee, Kelvin P; Nakshatri, Harikrishna; Allen, John; Guo, Yi; Sun, Ramon C; Guo, Jingchuan; Bian, Jiang. (2025). GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.. JAMA oncology, 11(10), 1186-1193. https://doi.org/10.1001/jamaoncol.2025.2681
MLA
Dai, Hao, et al. "GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.." JAMA oncology, 2025. https://doi.org/10.1001/jamaoncol.2025.2681
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesi..." RPEP-10592. Retrieved from https://rethinkpeptides.com/research/dai-2025-glp1-receptor-agonists-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.